US4719047A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anthracene derivatives
Assignee: SmithKline Beecham Corp
•
Filing: 1985-04-22
•
Granted: 1988-01-12
•
Expires: 2005-04-22
Abstract
Abstract The present invention relates to compounds of formula (I) ##STR1## wherein Ar is an anthracene or substituted anthracene ring system; R 1 is a C 1-3 alkylene moiety; R 2 is hydrogen or a C 1-6 alkyl group; R 3 is a hydroxy C 1-6 alkyl group; R 4 and R 5 are the same or different and are hydrogen, C 1-6 alkyl or hydroxy C 1-6 alkyl, esters thereof derived from condensation of carboxy acids and hydroxyl groups of R 3 , R 4 , and R 5 ; Acid addition salts thereof, which have been found useful for the treatment of tumors in mammals.
Inventors
- 👤 Kenneth W. Bair
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 10:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/045; C; C07; C07C; C07C215/00; C07C215/02; C07C215/04; C07C215/20; A61P; A61P31/00; A61P35/00; C07C205/00; C07C205/13; C07C205/14; C07C205/15; C07C215/06; C07C215/10; C07C215/22; C07C215/28; C07C215/42; C07C217/00; C07C217/02; C07C217/48; C07C217/54; C07C217/56; C07C217/58; C07C255/00; C07C255/49; C07C255/58; C07C317/00; C07C317/26; C07C317/32; C07C323/00; C07C323/23; C07C323/31; C07C323/32; C07D; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08; C07D263/00; C07D263/52; C07D263/62; C07D263/64; C07D295/00; C07D295/04; C07D295/12; C07D295/135; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; C07D319/00; C07D319/04; C07D319/06; C07J; C07J63/00; C07J63/008; C07C2601/00; C07C2601/12; C07C2601/14; C07C2603/00; C07C2603/02; C07C2603/04; C07C2603/22; C07C2603/24; C07C2603/26; C07C2603/40; C07C2603/42; C07C2603/48; C07C2603/50
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
6 words
A pharmaceutically acceptable salt of 2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino)-2-methyl-1,3-propanediol.
Claim 2
Dependent Claim
6 words
A pharmaceutically acceptable salt of 2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino)-2-methyl-1,3-propanediol.
Claim 3
Dependent Claim
6 words
The hydrochloride salt of claim 1.
Claim 4
Dependent Claim
6 words
The p-toluenesulfonic salt of claim 1.
Claim 5
Dependent Claim
1 words
2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino)-2-methyl-1,3,-propanediol.
Claim 6
Dependent Claim
1 words
2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino)-2-methyl-1,3,-propanediol.
References Cited (Backward Citations)
SU182132A1
Cited
US2734920A
Cited
US2194294A
Cited
US2865925A
Cited
US3052722A
Cited
US3322758A
Cited
DE2123992A1
Cited
US4034040A
Cited
US4197249A
Cited
US4258181A
Cited
US4211726A
Cited
EP0125702A2
Cited
US4530800A
Cited
US4532344A
Cited
US4551282A
Cited
US4511582A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-01-11 | 1991-07-13 | 1992-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-01-11 | 1995-07-13 | 1996-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-01-11 | 1999-07-13 | 2000-01-12 | $7700.00 | Window Closed / Lapsed |